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Background: Clinical trials leading to regulatory approval, or registration trials, play a central role in the development
of drugs and medical devices. The contribution of support staff, such as the clinical research coordinator (CRC) and
administrative officers, in registration trials is now widely recognized. Attending to serious adverse events is an
important duty of the CRC and investigators alike, and managing these complications and compensation constitutes a
key responsibility. We retrospectively examined the frequency of serious adverse events and compensation events
reported from 2007 through 2011 at Tokushima University Hospital, an academic hospital in rural Japan. We present
herein the results of our analysis.
Results: Over the five-year period, 284 subjects participating in 106 registration trials experienced a total of 43 serious
adverse events, and eight compensation events were documented. Among the serious adverse events, 35 (81.4%) were
considered not related to the investigational drug, and 17 (39.5%) resulted in withdrawal of the study drug. Patients
with malignant diseases experienced serious adverse events significantly more frequently compared to those with
non-malignant diseases (28.3% versus 8.2%, respectively; P < 0.01).
Conclusions: The CRC should be vigilant for serious adverse events in oncology clinical trials due to the generally
higher frequency of these complications in subjects with malignancy. However, on an individual basis, the CRC may
be seldom involved in the process for compensating serious adverse events. Therefore, the CRC’s ability to share
such experiences may serve as an opportunity for educating clinical trial support staff at the study site as well as
those at other sites. However, further study is warranted to determine the role of the clinical trial support staff in
optimizing methods for managing adverse events requiring compensation in registration trials.
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Clinical research plays an important role in improving
the quality of medical practice. In particular, registration
trials leading to the approval of drugs and medical de-
vices are paramount in the development of drugs and
medical devices. In 1996, the Good Clinical Practice (GCP)
was introduced as a global standard, and since the Japanese
introduction of it in 1997, the infrastructure for registra-
tion trials in Japan has improved. The contribution of* Correspondence: niseko@tokushima-u.ac.jp
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ordinators (CRC) and administrative officers, is now widely
recognized.
CRC must engage not only in the scientific and ethical
pursuit of registration trials, but also in assuring standards
of quality by coordinating the activities and conduct of par-
ticipants, investigators, sponsors, and various hospital staff.
Among these duties, adverse event management, including
proper and timely reporting to sponsors, is a key responsi-
bility. CRC, as well as investigators, should pay close atten-
tion to serious adverse events, partly because these events
may lead to compensation events which require additional
resources and the involvement of administrative officers.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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staff may have limited experience dealing with serious ad-
verse events and compensation. Therefore, reviewing the
shared experience of the CRC may offer a valuable oppor-
tunity for collecting and analyzing data on the frequency of
these events, and provide some insight into appropriate
methods for managing them. Accordingly, we retrospect-
ively examined the incidence of serious adverse events and
related compensation at Tokushima University Hospital.
We present herein the results of our analysis.
Methods
We retrospectively reviewed records from the institutional
review board (IRB) of Tokushima University Hospital for
the period 2007 through 2011. A serious adverse event
was defined by the criteria established in the Inter-
national Conference on Harmonisation (ICH) harmo-
nised tripartite guideline E2A [1]. We classified a serious
adverse event as an untoward medical occurrence which
at any dose: 1) resulted in death, 2) was life-threatening,
3) required inpatient hospitalisation or prolonged an
existing hospitalisation, 4) resulted in persistent or signifi-
cant disability or incapacity, 5) was a congenital anomaly/
birth defect, or 6) others. We compared the frequency of
events and subjects stratified by malignant and non-
malignant diseases and applied a chi-squared test to analyze
differences. A two-sided P-value <0.05 was considered to be
statistically significant. This study was approved by the
Ethics Committee of Tokushima University Hospital.
Results
Number of registration trials and subjects over the
five-year period
Table 1 presents the number of registration trials ap-
proved by the IRB at Tokushima University Hospital
each year as well as the frequency of subjects with ma-
lignant diseases and non-malignant diseases. Data for
the year 2007 pertained to trials continuing from previous
years as well as those approved in the current year. For
2008–2011, clinical trials approved in each respective year
were included. As shown in Table 1, clinical studies inTable 1 Frequency of studies and subjects in oncology and n
Hospital: 2007 to 2011
Number of registration trials (%)
Malignant diseases Non- malignant diseases Total
2007 11 (23.4) 36 (76.6) 47 (100)
2008 1 (6.7) 14 (93.3) 15 (100)
2009 4 (28.6) 10 (71.4) 14 (100)
2010 4 (28.6) 10 (71.4) 14 (100)
2011 5 (31.3) 11 (68.7) 16 (100)
Total 25 (23.6) 81 (76.4) 106 (100non-malignant diseases comprised a greater proportion of
registration trials conducted at Tokushima University
Hospital compared to those in malignant diseases.
Frequency of serious adverse events
As indicated in Table 2, a total of 43 serious adverse
events were reported during the five-year period. Among
these, a relationship between the adverse event and in-
vestigational drug was ruled out in 14 (66.6%) of 21
events occurring in patients with malignant diseases and
in 21 of 22 (95.5%) events in those with non-malignant
diseases. Eleven of 21 (52.4%) events in patients with
malignant diseases and 6 of 22 (27.3%) events in those
with non-malignant diseases led to the withdrawal of the
study drug. Examining the numbers of subjects with se-
vere adverse events, a significantly greater proportion of
subjects with malignant disease (28.3%; 15 of 53) experi-
enced serious adverse events compared to those with
non-malignant disease (8.2%; 19 of 231; P < 0.01).
Subjects with multiple serious adverse events
Among the 25 oncology registration trials, two subjects
experienced two serious adverse events, and two sub-
jects experienced three. None of the subjects in the on-
cology trials experienced more than three. Among the
81 non-oncology registration trials, one subject experi-
enced two serious adverse events, and another had three.
Similar to the oncology trials, none of the subjects in the
non-oncology trials had more than three (Table 3).
Frequency of compensation events and subjects seeking
compensation
Over the five-year period, eight compensation events
were reported in a total of seven subjects at Tokushima
University Hospital. Among these, seven compensation
events occurred during the oncology registration trials,
and one was associated with a non-oncology trial.
Discussion
Among the various roles assigned to the CRC, adverse
event management, including proper and timely reportingon-oncology registration trials at Tokushima University
Number of subjects (%)
Malignant diseases Non- malignant diseases Total
28 (20.7) 107 (79.3) 135 (100)
5 (7.7) 60 (92.3) 65 (100)
8 (24.2) 25 (75.8) 33 (100)
10 (31.3) 22 (68.7) 32 (100)
2 (10.5) 17 (89.5) 19 (100)
) 53 (18.7) 231 (81.3) 284 (100)
Table 2 Annual and total number of serious adverse events
in subjects with malignant diseases and non-malignant
diseases
Number of serious adverse events
Malignant diseases Non- malignant diseases Total
2007 5 3 8
2008 4 3 7
2009 6 3 9
2010 2 9 11
2011 4 4 8
Total 21 22 43
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ious adverse events and compensation may differ across
study sites depending on the types of registration trials,
investigational drugs, and underlying diseases prevalent in
the study population. Among the published studies of
Japanese university hospitals, Fukutomi et al. [2] cited
42 serious adverse events and 14 compensation events in
1085 participants over 4.25 years. Yamada et al. [3] re-
ported a total of 78 serious adverse events occurring in
725 participants over three years, whereas Suzuki et al. [4]
documented 10 compensation events during a 10-year
period. In the present study, 43 serious adverse events and
8 compensation events were reported in 284 subjects over
five years, the occurrence of which we consider to be in
line with previous reports.
Adverse event management, including proper and
timely reporting to sponsors, is an important responsi-
bility of the CRC [5]. A key function of managing serious
adverse events is the collection of data on whether or
not the subject sought consultation from other medical
institutions. Yamada et al. [3] described the development
of a manual in an urban university hospital to facilitate
the collection of data from physicians in other hospitals
with whom subjects consulted for managing serious
adverse events during clinical trials. In our rural area,
communication between hospitals is readily facilitated,
thereby warranting efforts to collect information from
other institutions.Table 3 Frequency of serious adverse events in subjects
with malignant diseases and non-malignant diseases






0 38 212 250
1 11 17 28
2 2 1 3
3 2 1 3
Total 53 231 284Compensation for injured and deceased research sub-
jects has been a long-standing issue [6]. In Japan, spon-
sors of registration trials are required to prepare for the
provision of compensation. Details of compensation are
not defined by regulation. Instead, the guideline by the
Japan Pharmaceutical Industry Legal Affairs Association
[7] is used by most of the sponsors. Japan has universal
health coverage by employee-based and community-based
social health insurance [8]. In the system, co-payment rate
is 30% in general, and the rest is paid by public insurance.
Acting of co-payment by sponsors is considered as com-
pensation in Japan. In serious cases, such as fatal cases,
monetary compensation is considered.
Because compensation is considered regardless of fault
even when the relationship between the adverse event
and investigational drug is indeterminate, the investi-
gator’s decision regarding the potential association is
highly important. In the present study, a relationship
could not be ruled out in 8 of the 43 serious events. Par-
ticipants’ consent for compensation is mandatory for
registration trials. Nevertheless, in most cases, staffs of
medical institution propose claims for compensation to
injured participants practically. In such cases, the CRC
should coordinate the efforts of sponsors, study partici-
pants, investigators, and administrative offices from all
institutions with the aim of protecting the subjects’
rights, and that is the first role of CRC in compensation.
In 2005, we developed a manual to manage compensa-
tion events following discussions with the administrative
office. In general, it takes time to decide relationship
between the adverse event and investigational drug, and
participants should pay their co-payment before the de-
cision. As a practice in Tokushima University Hospital,
patients’ payment of co-payment is postponed until the
final decision of the relationship. Even if payment of co-
payment by sponsors starts, it will be ceased when the
condition becomes stable. Long time follow-up of partic-
ipants is also important and these points are shown in
our manual. Suzuki et al. [4] also compiled a checklist to
manage compensation at a Japanese university hospital.
Since individual CRC may seldom participate in com-
pensation events involving their assigned subjects, it may
be helpful for those who have dealt with such events to
share their experiences with other CRC at the study site as
well as with those from other sites.
In the present study, subjects with malignant disease
experienced serious adverse events more often than those
with non-malignant disease. Conversely, the relationship
with the investigational drug was ruled out more frequently
in cases with non-malignant diseases than in those with
malignant diseases. These findings suggest that the differ-
ence was not related to the higher incidence of disease-
related death among oncology trials. In a Spanish survey of
CRCs attending an educational course on oncology clinical
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tasks performed by CRCs were categorized as "monitoring
activities," and included patient registration/randomization,
recruitment follow-up, case report form completion, col-
laboration with the clinical research associates (CRA), ser-
ious adverse events reporting, handling of investigator files,
and preparing the site for audits, and attending audits. Al-
though the basic tasks of CRC do not differ, the present
findings indicate that CRC should pay close attention to
the serious adverse events in oncology clinical trials due to
the potentially higher frequency of serious complications
in these types of studies.
Conclusions
The present study evaluated serious adverse events and
compensation in registration trials restricted to a univer-
sity hospital in rural Japan. We found that subjects with
malignant diseases experienced serious adverse events
and required compensation more frequently than those
with non-malignant diseases. From the perspective of
the clinical trial support staff, it is necessary to establish
more effective systems for managing serious adverse
events and compensation. However, given the limitations
of our retrospective study, further research is warranted
to determine the role of clinical trial support staff in de-
veloping a suitable infrastructure for these systems in
clinical research.
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